{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:21Z","timestamp":1787003721837,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1123502C"],"award-info":[{"award-number":["TCVGH-1123502C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07159-3","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:59:46Z","timestamp":1751410786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associations of cystatin C with incident chronic kidney disease and all-cause mortality in patients with normal glucose tolerance and prediabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Guan-Hong","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Heng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"7159_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Global","year":"2020","unstructured":"Global National burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"7159_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.ki.5002343","volume":"72","author":"AS Levey","year":"2007","unstructured":"Levey, A. S. et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 72, 247\u2013259 (2007).","journal-title":"Kidney Int."},{"key":"7159_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375, 2073\u20132081 (2010).","journal-title":"Lancet"},{"key":"7159_CR4","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(08)60952-6","volume":"371","author":"CP Wen","year":"2008","unstructured":"Wen, C. P. et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371, 2173\u20132182 (2008).","journal-title":"Lancet"},{"key":"7159_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrneph.2017.63","volume":"13","author":"R Vanholder","year":"2017","unstructured":"Vanholder, R. et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat. Rev. Nephrol. 13, 393\u2013409 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"7159_CR6","first-page":"1864","volume":"317","author":"AK Bello","year":"2017","unstructured":"Bello, A. K. et al. Assess. Global Kidney Health Care Status JAMA 317, 1864\u20131881 (2017).","journal-title":"Assess. Global Kidney Health Care Status JAMA"},{"key":"7159_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/ajkd.2000.8237","volume":"36","author":"E Coll","year":"2000","unstructured":"Coll, E. et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 36, 29\u201334 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"7159_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl. J. Med. 367, 20\u201329 (2012).","journal-title":"N Engl. J. Med."},{"key":"7159_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1681\/ASN.2010050483","volume":"22","author":"CA Peralta","year":"2011","unstructured":"Peralta, C. A. et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J. Am. Soc. Nephrol. 22, 147\u2013155 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7159_CR10","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2337\/dc11-2220","volume":"35","author":"AS Krolewski","year":"2012","unstructured":"Krolewski, A. S. et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 35, 2311\u20132316 (2012).","journal-title":"Diabetes Care"},{"key":"7159_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens, P. E. & Levin, A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825\u2013830 (2013).","journal-title":"Ann. Intern. Med."},{"key":"7159_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.5114\/aoms.2019.83511","volume":"16","author":"CC Ma","year":"2019","unstructured":"Ma, C. C., Duan, C. C., Huang, R. C. & Tang, H. Q. Association of circulating cystatin C levels with type 2 diabetes mellitus: a systematic review and meta-analysis. Arch. Med. Sci. 16, 648\u2013656 (2019).","journal-title":"Arch. Med. Sci."},{"key":"7159_CR13","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41598-018-38286-9","volume":"9","author":"AV Cheuiche","year":"2019","unstructured":"Cheuiche, A. V., Queiroz, M., Azeredo-da-Silva, A. L. F. & Silveiro, S. P. Performance of cystatin C-based equations for estimation of glomerular filtration rate in diabetes patients: A Prisma-Compliant systematic review and meta-analysis. Sci. Rep. 9, 1418 (2019).","journal-title":"Sci. Rep."},{"key":"7159_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539\u2013553 (1998).","journal-title":"Diabet. Med."},{"key":"7159_CR15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"2","year":"2022","unstructured":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 45, S17\u2013S38 (2022).","journal-title":"Diabetes Care"},{"key":"7159_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"7159_CR17","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa043161","volume":"352","author":"MG Shlipak","year":"2005","unstructured":"Shlipak, M. G. et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl. J. Med. 352, 2049\u20132060 (2005).","journal-title":"N Engl. J. Med."},{"key":"7159_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7326\/0003-4819-145-4-200608150-00003","volume":"145","author":"MG Shlipak","year":"2006","unstructured":"Shlipak, M. G. et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med. 145, 237\u2013246 (2006).","journal-title":"Ann. Intern. Med."},{"key":"7159_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7326\/0003-4819-147-1-200707030-00004","volume":"147","author":"V Menon","year":"2007","unstructured":"Menon, V. et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann. Intern. Med. 147, 19\u201327 (2007).","journal-title":"Ann. Intern. Med."},{"key":"7159_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00125-018-4567-5","volume":"61","author":"HM Colhoun","year":"2018","unstructured":"Colhoun, H. M. & Marcovecchio, M. L. Biomarkers of diabetic kidney disease. Diabetologia 61, 996\u20131011 (2018).","journal-title":"Diabetologia"},{"key":"7159_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"17","author":"RA DeFronzo","year":"2021","unstructured":"DeFronzo, R. A., Reeves, W. B. & Awad, A. S. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 17, 319\u2013334 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"7159_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.121.053766","volume":"144","author":"AJ Nelson","year":"2021","unstructured":"Nelson, A. J. et al. Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community. Circulation 144, 74\u201384 (2021).","journal-title":"Circulation"},{"key":"7159_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clinbiochem.2018.01.005","volume":"53","author":"JD Machado","year":"2018","unstructured":"Machado, J. D. et al. Combined creatinine-cystatin C CKD-EPI equation significantly underestimates measured glomerular filtration rate in people with type 2 diabetes mellitus. Clin. Biochem. 53, 43\u201348 (2018).","journal-title":"Clin. Biochem."},{"key":"7159_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/dc13-1899","volume":"37","author":"A Tsuda","year":"2014","unstructured":"Tsuda, A. et al. Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes Care. 37, 596\u2013603 (2014).","journal-title":"Diabetes Care"},{"key":"7159_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.issn.0366-6999.2010.06.020","volume":"123","author":"HX Li","year":"2010","unstructured":"Li, H. X., Xu, G. B., Wang, X. J., Zhang, X. C. & Yang, J. M. Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. Chin. Med. J. (Engl). 123, 745\u2013751 (2010).","journal-title":"Chin. Med. J. (Engl)"},{"key":"7159_CR26","doi-asserted-by":"publisher","first-page":"824279","DOI":"10.3389\/fendo.2022.824279","volume":"13","author":"N Wang","year":"2022","unstructured":"Wang, N. et al. Serum cystatin C trajectory is a marker associated with diabetic kidney disease. Front. Endocrinol. (Lausanne). 13, 824279 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"7159_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13300-016-0158-y","volume":"7","author":"C Mende","year":"2016","unstructured":"Mende, C., Katz, A. & Cystatin, C. Creatinine-based estimates of glomerular filtration rate in Dapagliflozin phase 3 clinical trials. Diabetes Ther. 7, 139\u2013151 (2016).","journal-title":"Diabetes Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07159-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T11:02:03Z","timestamp":1751799723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7159"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07159-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23092"}}